Renovo (RNVO)
market vs.
industry GROWTH & VALUE
| Trailing 12m | ||||
| PE Ratio (ttm) | 103.6 |
|
|
|
| PEG Ratio (ttm) |
|
|
||
| EPS Growth (ttm) | % |
|
|
|
| Dividend Yield (ttm) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 1.05 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 30th Sep | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | -12.5% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 30 September 2012, Renovo Group Plc revenues was not reported. Net income before extraordinary items totaled L313K vs. loss of L120K. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 30th Sep '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 0 | 0 | 1 |
Renovo Group plc is a biopharmaceutical product company. As of September 30, 2011, the Company had an ongoing clinical trial, Prevascar, for improving the appearance of scarring in the skin. On May 26, 2011, the Company announced that the data from the Prevascar proof of concept clinical trial involving 1centimeter skin incisions in volunteers of African Ancestral Group origin showed a significant improvement in scar width (p=0.03) of approximately 12% one month post-wounding, as measured from histological sections of the excised scars. The differences were significant for one of the four doses of Prevascar tested against placebo. During the fiscal year ended September 30, 2011, all of the Company’s other pipeline activities were ceased.
Directors: David Blain (CFO) 51,
No. of Employees: 0 No. of Shareholders: n/a
| Last Annual | September 30th, 2012 |
| Last Interim | September 30th, 2012 |
| Shares in Issue | 151,124,038 |
| Free Float | 94.1m (62.3%) |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Manchester Incubator Building,48 Grafton Street, MANCHESTER, M13 9XX, United Kingdom |
| Web | http://www.renovo.com/ |
| Phone | +44 161 2767100 |
| Contact | () |
| Registrar | Capita Registrars (Kent) |
| Auditors | Deloitte LLP |
| 21st Mar | Transaction in Own Shares |
| 20th Mar | Transaction in Own Shares |
| 19th Mar | Transaction in Own Shares |
| 12th Mar | Transaction in Own Shares |
| 14th Feb | Transaction in Own Shares |
| 13th Feb | Transaction in Own Shares |
Recent ↓
